CUMULATIVE INDEX Volume 1, Numbers 1-12, Pages 1-144 June 1999May 2000

A

ablational therapies, hepatic tumors, 8:85

angiogenesis, matrix metalloproteinase, 1:9

apoptosis breast cancer, 2:17 p53-dependent, 9:105 phospholipase A2, 6:69

B

biomarkers, DNA adducts, 3:31

bisphosphonates, cancer, 1:6

bladder cancer, N-acetyltransferase 2, 10:117

breast cancer apoptosis, 2:17 molecular markers, 7:75 paracrine regulation, 11:125

C

cancer biomarkers, DNA adducts, 3:31

cancer immunity, T cell, 11:129

cancer, high-dose chemotherapy, 7:78, 8:93

cell cycle arrest, prostate cancer, 2:17

cell cycle regulation, 10:111

chemotherapy and radiation, pancreatic cancer, 3:25

chemotherapy, high-dose, 7:78, 8:93

cholangiocarcinoma, cytokines, 12:141

colon cancer, colitis, 4:43

colorectal cancer, cyclooxygenase-2, 6:67 juvenile polyposis, 1:8

copper, liver cancer, 4:45

cyclooxygenase-2, colorectal cancer, 6:67

cytokines, cholangiocarcinoma, 12:141

D

dendritic cells, prostate cancer, 8:89

DNA adducts, biomarkers for cancer, 3:31

DNA methylation, cancer, 12:133

E

epidemiology, cancer, 2:13

esophageal cancer iron, 3:33 photodynamic therapy, 1:2

F

fluorescence bronchoscopy, lung cancer, 5:56

follicular lymphoma vaccine, 9:97

G

gender, lung cancer, 11:121

gene therapy, lung cancer, 1:1

gene, TbR-I(6A), 10:114

genetic susceptibility, head and neck cancer, 12:136

genomic instability, 7:73

glucose, malignant tissues. 5:51

H

head and neck cancer, genetic susceptibility, 12:136

hepatic tumors, ablational therapies, 8:85

hormone, steroid, 9:100

hypoxia, cancer cells, 1:11

I

iron, esophageal cancer, 3:33

L

liposomes, stealth, 6:65

liver cancer, copper, 4:45

lung cancer fluorescence bronchoscopy, 5:56 gender, 11:121 gene therapy, 1:1 photodynamic therapy, 1:2

lymphoma vaccine, 9:97

M

malignancies, secondary, and radiation exposure, 6:61

malignant tissues, glucose, 5:51

malignant transformation, 5:49

matrix metalloproteinase, angiogenesis, 1:9

melanoma, tumor vaccines, 4:37

metalloproteinases, tissue inhibitors, 8:91

MGI-114, prostate cancer, 4:41

microarray analysis, prostate cancer, 9:103

molecular markers, breast cancer, 7:75

N

N-acetyltransferase-2, bladder cancer, 10:117

NIH, peer review process, 5:59

nuclear matrix proteins, 2:15

P

pancreatic cancer, chemotherapy and radiation, 3:25

paracrine regulation, breast cancer, 11:25

peer review process, NIH, 5:59

phospholipase A2, apoptosis, 6:69

photodynamic therapy, lung cancer, 1:2

polyamines, prostate cancer, 11:128

polyposis, colorectal cancer, 1:8

prostate cancer cell cycle arrest, 2:17 dendritic cells, 8:89 MGI-114, 4:41 microarray analysis, 9:103 polyamines, 11:128 telomerase, 5:54

prostate, stromal-epithelial interactions, 3:28

proteins, nuclear matrix, 2:15

R

radiation and chemotherapy, pancreatic cancer, 3:25

radiation exposure, secondary malignancies, 6:61

renal cell carcinoma, telomerase, 5:54

RNA vaccine, 10:109

S

stealth liposomes, 6:65

steroid hormone receptor action, 9:100

T

T cell, cancer immunity, 11:129

telomerase, prostate and renal cell carcinoma, 5:54

V

vaccine follicular lymphoma, 9:97 RNA, 10:109 melanoma, 4:37